Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Rating of “Moderate Buy” from Brokerages

Posted by Geri Gentry on Aug 11th, 2026

Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $15.00.

Several brokerages recently weighed in on ARDX. HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Ardelyx in a research note on Friday. TD Cowen decreased their price target on Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Friday. Zacks Research downgraded Ardelyx from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Weiss Ratings lowered Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 29th. Finally, Citigroup cut their price objective on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Monday.

Check Out Our Latest Research Report on ARDX

Ardelyx Stock Performance

NASDAQ:ARDX opened at $4.00 on Tuesday. The stock has a market capitalization of $996.76 million, a price-to-earnings ratio of -18.18 and a beta of 0.70. Ardelyx has a 52 week low of $3.90 and a 52 week high of $8.40. The company has a quick ratio of 3.28, a current ratio of 3.49 and a debt-to-equity ratio of 1.37. The firm has a 50 day moving average of $5.34 and a 200 day moving average of $6.04.

Ardelyx (NASDAQ:ARDX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Ardelyx had a negative return on equity of 35.57% and a negative net margin of 12.35%.The firm had revenue of $120.88 million during the quarter, compared to analysts’ expectations of $121.03 million. During the same period in the prior year, the firm posted ($0.08) earnings per share. Ardelyx’s revenue for the quarter was up 34.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Ardelyx will post -0.1 earnings per share for the current fiscal year.

Insider Activity at Ardelyx

In other news, insider Eric Duane Foster sold 7,998 shares of Ardelyx stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total transaction of $50,147.46. Following the completion of the sale, the insider directly owned 417,972 shares in the company, valued at approximately $2,620,684.44. The trade was a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Mike Kelliher sold 7,248 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total transaction of $45,444.96. Following the sale, the insider directly owned 357,418 shares in the company, valued at $2,241,010.86. This trade represents a 1.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 24,572 shares of company stock worth $154,066. 5.30% of the stock is owned by insiders.

Institutional Trading of Ardelyx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Ardelyx in the second quarter valued at $119,874,000. AIGH Capital Management LLC purchased a new stake in Ardelyx in the 2nd quarter valued at about $16,320,000. Bank of America Corp DE raised its holdings in Ardelyx by 88.8% in the 2nd quarter. Bank of America Corp DE now owns 5,527,988 shares of the biopharmaceutical company’s stock valued at $21,670,000 after buying an additional 2,600,080 shares during the period. State Street Corp lifted its position in Ardelyx by 22.6% in the fourth quarter. State Street Corp now owns 11,912,339 shares of the biopharmaceutical company’s stock valued at $69,449,000 after buying an additional 2,193,649 shares during the last quarter. Finally, Rubric Capital Management LP acquired a new position in Ardelyx in the first quarter valued at about $11,147,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

About Ardelyx

(Get Free Report)

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.